Overview Dividends

(ILMN) Illumina - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4523271090

Sequencers, Arrays, Consumables, Reagents, Library Prep

ILMN EPS (Earnings per Share)

EPS Growth (3Y CAGR): 127.36%
EPS Trend (3Y Correlation): 83.1%

ILMN Revenue

Revenue Growth (3Y CAGR): -0.03%
Revenue Trend (3Y Correlation): -49.9%

Description: ILMN Illumina October 30, 2025

Illumina, Inc. (NASDAQ: ILMN) designs, manufactures, and sells sequencing- and array-based platforms and consumables that enable whole-genome, exome, and targeted-region analysis for research, clinical, and consumer genomics applications across the Americas, Europe, Greater China, APAC, the Middle East, and Africa.

In FY 2023 the company generated roughly $4.5 billion in revenue, growing about 13 % year-over-year, with R&D expenditures representing ~20 % of sales-a reflection of its focus on maintaining a technological edge in next-generation sequencing (NGS). Illumina commands an estimated 70 % share of the global NGS market, driven by declining sequencing costs (now under $600 per human genome) and expanding clinical-diagnostic use cases such as non-invasive prenatal testing and oncology-focused liquid biopsies. The firm’s growth is also tied to broader sector trends, including increasing investment in personalized medicine and the rising demand for high-throughput genomic data in drug discovery.

For a deeper quantitative breakdown of Illumina’s valuation metrics, the ValueRay platform offers a concise, data-driven dashboard you may find useful.

ILMN Stock Overview

Market Cap in USD	18,988m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	2000-07-28

ILMN Stock Ratings

Growth Rating	-64.5%
Fundamental	74.7%
Dividend Rating	-
Return 12m vs S&P 500	-31.1%
Analyst Rating	3.68 of 5

ILMN Dividends

Currently no dividends paid

ILMN Growth Ratios

Growth Correlation 3m	2.3%
Growth Correlation 12m	-32.5%
Growth Correlation 5y	-92.8%
CAGR 5y	-19.94%
CAGR/Max DD 3y (Calmar Ratio)	-0.28
CAGR/Mean DD 3y (Pain Ratio)	-0.48
Sharpe Ratio 12m	-1.01
Alpha	-44.50
Beta	1.398
Volatility	40.87%
Current Volume	1125.1k
Average Volume 20d	1651.7k
Stop Loss	116.2 (-4.7%)
Signal	0.27

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (703.0m TTM) > 0 and > 6% of Revenue (6% = 257.2m TTM)

FCFTA 0.16 (>2.0%) and ΔFCFTA 7.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 19.45% (prev 31.85%; Δ -12.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.18 (>3.0%) and CFO 1.12b > Net Income 703.0m (YES >=105%, WARN >=100%)

Net Debt (1.53b) to EBITDA (1.27b) ratio: 1.20 <= 3.0 (WARN <= 3.5)

Current Ratio 1.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (157.0m) change vs 12m ago -1.88% (target <= -2.0% for YES)

Gross Margin 66.20% (prev 63.94%; Δ 2.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 70.33% (prev 73.00%; Δ -2.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.96 (EBITDA TTM 1.27b / Interest Expense TTM 125.0m) >= 6 (WARN >= 3)

Altman Z'' 1.40

(A) 0.14 = (Total Current Assets 2.80b - Total Current Liabilities 1.96b) / Total Assets 6.18b

(B) -0.12 = Retained Earnings (Balance) -726.0m / Total Assets 6.18b

(D) -0.19 = Book Value of Equity -736.0m / Total Liabilities 3.80b

Total Rating: 1.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.74

1. Piotroski 8.0pt = 3.0

2. FCF Yield 4.93% = 2.46

3. FCF Margin 23.33% = 5.83

4. Debt/Equity 1.08 = 1.94

5. Debt/Ebitda 1.20 = 1.47

6. ROIC - WACC (= 5.70)% = 7.12

7. RoE 29.98% = 2.50

8. Rev. Trend -49.94% = -3.75

9. EPS Trend 83.07% = 4.15

What is the price of ILMN shares?

As of November 08, 2025, the stock is trading at USD 121.90 with a total of 1,125,054 shares traded.
Over the past week, the price has changed by -1.33%, over one month by +26.09%, over three months by +27.64% and over the past year by -21.43%.

Is Illumina a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Illumina (NASDAQ:ILMN) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 74.74 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ILMN is around 90.46 USD . This means that ILMN is currently overvalued and has a potential downside of -25.79%.

Is ILMN a buy, sell or hold?

Illumina has received a consensus analysts rating of 3.68. Therefor, it is recommend to hold ILMN.

Strong Buy: 7
Buy: 5
Hold: 11
Sell: 2
Strong Sell: 0

What are the forecasts/targets for the ILMN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	115.9	-4.9%
Analysts Target Price	115.9	-4.9%
ValueRay Target Price	102.2	-16.2%

ILMN Fundamental Data Overview November 04, 2025

Market Cap USD = 18.99b (18.99b USD * 1.0 USD.USD)
P/E Trailing = 27.6996
P/E Forward = 20.284
P/S = 4.4282
P/B = 6.7593
P/EG = 0.622
Beta = 1.398
Revenue TTM = 4.29b USD
EBIT TTM = 995.0m USD
EBITDA TTM = 1.27b USD
Long Term Debt = 1.49b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 20.29b USD (18.99b + Debt 2.58b - CCE 1.28b)
Interest Coverage Ratio = 7.96 (Ebit TTM 995.0m / Interest Expense TTM 125.0m)
FCF Yield = 4.93% (FCF TTM 1.00b / Enterprise Value 20.29b)
FCF Margin = 23.33% (FCF TTM 1.00b / Revenue TTM 4.29b)
Net Margin = 16.40% (Net Income TTM 703.0m / Revenue TTM 4.29b)
Gross Margin = 66.20% ((Revenue TTM 4.29b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 65.63%)
Tobins Q-Ratio = 3.28 (Enterprise Value 20.29b / Total Assets 6.18b)
Interest Expense / Debt = 1.94% (Interest Expense 50.0m / Debt 2.58b)
Taxrate = 31.82% (70.0m / 220.0m)
NOPAT = 678.4m (EBIT 995.0m * (1 - 31.82%))
Current Ratio = 1.43 (Total Current Assets 2.80b / Total Current Liabilities 1.96b)
Debt / Equity = 1.08 (Debt 2.58b / totalStockholderEquity, last quarter 2.38b)
Debt / EBITDA = 1.20 (Net Debt 1.53b / EBITDA 1.27b)
Debt / FCF = 1.53 (Net Debt 1.53b / FCF TTM 1.00b)
Total Stockholder Equity = 2.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.38% (Net Income 703.0m / Total Assets 6.18b)
RoE = 29.98% (Net Income TTM 703.0m / Total Stockholder Equity 2.35b)
RoCE = 25.95% (EBIT 995.0m / Capital Employed (Equity 2.35b + L.T.Debt 1.49b))
RoIC = 15.69% (NOPAT 678.4m / Invested Capital 4.32b)
WACC = 9.99% (E(18.99b)/V(21.56b) * Re(11.17%) + D(2.58b)/V(21.56b) * Rd(1.94%) * (1-Tc(0.32)))
Discount Rate = 11.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
[DCF Debug] Terminal Value 67.80% ; FCFE base≈818.4m ; Y1≈822.4m ; Y5≈881.2m
Fair Price DCF = 62.78 (DCF Value 9.65b / Shares Outstanding 153.7m; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: 83.07 | EPS CAGR: 127.4% | SUE: 0.67 | # QB: 0
Revenue Correlation: -49.94 | Revenue CAGR: -0.03% | SUE: 1.05 | # QB: 1

Additional Sources for ILMN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle